Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVEMIR FLEXPEN vs LEVEMIR INNOLET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Type 1 diabetes mellitus,Type 2 diabetes mellitus
FDA: Treatment of diabetes mellitus (type 1 and type 2) to improve glycemic control,Off-label: Gestational diabetes, hyperglycemia in hospitalized patients
Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
Terminal elimination half-life approximately 5-7 hours in children (<6 years: 3-4 hours); provides flat, prolonged pharmacokinetic profile over 24 hours with no pronounced peak.
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Metabolized via insulin-degrading enzyme (IDE); less susceptible to hepatic degradation.
Insulin detemir is metabolized via non-CYP450 pathways, primarily proteolytic degradation. The main metabolite is inactive.
Renal (30-40% unchanged), remainder hepatically metabolized and excreted in bile/feces; negligible fecal elimination of parent drug.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
>98% bound to albumin.
>98% bound to albumin; binding is reversible and saturated at therapeutic concentrations.
0.12 L/kg (intravenous); indicates distribution primarily into extracellular fluid.
Volume of distribution is approximately 0.26–0.38 L/kg, reflecting distribution primarily into interstitial fluid.
Subcutaneous: approximately 60-65% (range 44-81% depending on injection site).
Subcutaneous: approximately 60–80% absolute bioavailability; not administered by other routes.
No specific dose adjustment required, but increased risk of hypoglycemia. Monitor glucose closely; dose reduction may be necessary.
For GFR <30 m L/min: consider dose reduction and more frequent monitoring due to decreased insulin clearance; start with lower doses and titrate cautiously. No specific dose adjustment guidelines for GFR 30-89 m L/min, but monitor closely.
No specific Child-Pugh based guidelines. Use with caution; dose adjustment may be needed due to altered glucose metabolism.
Child-Pugh Class A (mild): no dose adjustment required. Child-Pugh Class B (moderate): start with lower doses and titrate slowly due to impaired gluconeogenesis and reduced insulin clearance. Child-Pugh Class C (severe): use with caution; consider starting at 50% of standard dose and titrate based on response.
Subcutaneous injection. For type 1 diabetes: initial 0.1-0.2 units/kg/day once daily or divided. For type 2 diabetes: initial 0.2-0.5 units/kg/day. Titrate based on glycemic response.
For children aged 2 years and older with type 1 diabetes: start at 0.2-0.5 units/kg subcutaneously once daily in the evening. For type 2 diabetes: limited data; based on adult dosing. Adjust dose based on blood glucose targets. Do not mix with other insulins.
Start at lower doses (e.g., 0.1-0.2 units/kg/day) due to increased risk of hypoglycemia. Titrate cautiously, monitor renal function and glucose closely.
In elderly patients (age ≥65 years), start at lower doses (e.g., 0.1 units/kg subcutaneously once daily) due to increased risk of hypoglycemia. Titrate slowly and monitor renal function. Avoid aggressive dose escalation.
Never share a Levemir Flex Pen between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
None
Hypoglycemia is the most common adverse reaction,Monitor blood glucose; adjust dose with changes in renal/hepatic function,Exercise caution in patients with hypokalemia or during illness/stress
Hypoglycemia: May be life-threatening; dose adjustment needed with renal/hepatic impairment,Medication errors: Do not confuse with other insulins; not for IV or IM use,Hypokalemia: Can cause low potassium, leading to cardiac arrhythmias,Fluid retention and heart failure: When used with thiazolidinediones (TZDs)
Hypoglycemia,Hypersensitivity to insulin detemir or any excipients
Hypoglycemia episodes,Hypersensitivity to insulin detemir or excipients,Not recommended for diabetic ketoacidosis (use short-acting insulin)
No specific food interactions, but meals high in fat may slow absorption and affect glycemic response. Avoid excessive alcohol intake as it can increase risk of hypoglycemia. Consistent carbohydrate intake is recommended for glycemic control. Grapefruit may affect insulin sensitivity but interaction is not well-documented.
No specific food interactions. Advise consistent carbohydrate intake to match insulin dose. Alcohol may increase hypoglycemia risk; avoid or limit alcohol consumption.
Insulin detemir (Levemir) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, there is no evidence of increased risk of fetal malformations; however, poor glycemic control is associated with fetal risks including congenital anomalies, macrosomia, and neonatal hypoglycemia. Insulin detemir does not cross the placenta in significant amounts. Close monitoring of glucose control is recommended throughout pregnancy.
Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first trimester; risks in second and third trimesters relate to maternal hyperglycemia, not drug. Poor glycemic control increases risk of fetal anomalies, macrosomia, neonatal hypoglycemia.
Insulin detemir is excreted in human breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.1. It is considered compatible with breastfeeding, as insulin is a peptide that is likely digested in the infant's gastrointestinal tract and poses no known risk. However, caution should be exercised and glucose monitoring of the mother may be necessary.
Insulin detemir is excreted in human milk in low amounts, unlikely to affect the infant. M/P ratio not reported. It is a peptide that is degraded in infant GI tract. Use during breastfeeding is considered compatible with caution to monitor infant blood glucose if maternal dose is high.
Pregnancy increases insulin resistance, especially in the second and third trimesters. Dose requirements may increase significantly, often by 2-3 times the pre-pregnancy dose. Close titration based on blood glucose monitoring is essential. Postpartum, doses typically return to pre-pregnancy levels rapidly. Insulin detemir has a flat action profile, which may be advantageous in pregnancy.
Pregnancy increases insulin requirements, especially in second and third trimesters. Dose adjustments typical: first trimester may require 0-20% reduction due to increased hypoglycemia risk; second trimester increase by 50-70%; third trimester increase by 100-150% above pre-pregnancy doses. Frequent monitoring and titration are essential.
Levemir is a long-acting insulin analog (detemir) with a duration of action up to 24 hours, often used for basal insulin coverage. It has a lower risk of hypoglycemia compared to NPH insulin due to its more predictable absorption. Do not mix with other insulins in the same syringe. Onset is 3-4 hours, peak is 6-8 hours, duration is up to 24 hours. Dose adjustments are needed in renal or hepatic impairment. Administer once or twice daily; if twice daily, evening dose should be given at bedtime or with the evening meal. Shake the Flex Pen gently before use to ensure uniform suspension.
Levemir (insulin detemir) is a long-acting basal insulin analog with a duration of action up to 24 hours. It has a lower risk of hypoglycemia compared to NPH insulin due to its flat pharmacokinetic profile. Administer once or twice daily at the same time(s) each day. Do not mix with other insulins in the same syringe. Store unopened vials/penfills in refrigerator; opened pens can be kept at room temperature (<30°C) for up to 42 days. Monitor renal and hepatic function as dose adjustments may be needed.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites to prevent lipodystrophy.,Do not use if the solution is cloudy or contains particles; it should be clear and colorless.,Store unopened pens in refrigerator at 2-8°C; once in use, keep at room temperature below 30°C and discard after 42 days.,Avoid alcohol consumption as it may increase risk of hypoglycemia.,Do not share your Flex Pen with others even if the needle is changed.,Monitor blood glucose regularly and keep a record.,Recognize symptoms of hypoglycemia (sweating, dizziness, confusion) and hyperglycemia (frequent urination, thirst, blurred vision).,Carry a source of fast-acting sugar (e.g., glucose tablets, juice) for hypoglycemia treatment.,Do not use if the insulin has been frozen or exposed to temperatures above 30°C.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites to avoid lipodystrophy.,Do not mix with other insulins; use a separate injection site if combining therapies.,Check blood glucose regularly and record results; know symptoms of hypoglycemia and hyperglycemia.,Do not use if solution appears cloudy or has particles; it should be clear and colorless.,Store unopened pens in refrigerator; opened pens can be kept at room temperature for up to 42 days away from heat or light.,Missed dose: take as soon as remembered unless next dose is due within 6 hours; never double dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVEMIR FLEXPEN vs LEVEMIR INNOLET, answered by our medical review team.
LEVEMIR FLEXPEN is a Antidiabetic (Long-Acting Insulin) that works by Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.. LEVEMIR INNOLET is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVEMIR FLEXPEN and LEVEMIR INNOLET depend on the specific clinical indication. These are both Antidiabetic (Long-Acting Insulin) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVEMIR FLEXPEN is: Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.. The standard adult dose of LEVEMIR INNOLET is: 0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVEMIR FLEXPEN and LEVEMIR INNOLET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVEMIR FLEXPEN is classified as Category C. Insulin detemir (Levemir) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, there is no evidence of increased risk of . LEVEMIR INNOLET is classified as Category C. Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.